title: Involvement of heparin cofactor II in chymotrypsin neutralization and in the pancreatic proteinase-antiproteinase interaction during acute pancreatitis in man.
abstract: Heparin cofactor II is a proteinase inhibitor which inhibits both chymotrypsin and thrombin, and displays great similarities with antithrombin III, the main inhibitor of thrombin in human plasma. Since acute pancreatitis is known to be associated with modification of the proteinase-antiproteinase equilibrium, we studied heparin cofactor II and antithrombin III as well as other biochemical and haematological parameters in 10 patients experiencing attacks of acute pancreatitis. Heparin cofactor II activity decreased during the first week of illness, while its antigen concentration remained subnormal. This discrepancy between antigen concentration and activity which persisted during the first week of illness was due both to complex formation of heparin cofactor II with its target proteinases and to partial proteolysis of the inhibitor. Heparin cofactor II was shown to form a complex with chymotrypsin in the plasma of such patients. Antithrombin III levels remained unchanged throughout the study, with no discrepancy between its activity and antigen concentration. No modification of haemostasis was shown either, except for a rise in the fibrinogen level during the first days of illness. It is concluded that, unlike antithrombin III, heparin cofactor II is involved in the proteinase-inhibitor equilibrium in patients with acute pancreatitis, and that heparin cofactor II might react as an inhibitor of pancreatic proteinases rather than an inhibitor of thrombin.
authors.affiliation: Laboratoire d'Hémostase, Hôpital Broussais, Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Toulon
authors.forename: G
authors.initials: G
authors.lastname: Chadeuf
authors.forename: J L
authors.initials: JL
authors.lastname: Bouillot
authors.forename: J
authors.initials: J
authors.lastname: Amiral
authors.forename: M
authors.initials: M
authors.lastname: Cambillau
authors.forename: Y
authors.initials: Y
authors.lastname: Sultan
authors.forename: M
authors.initials: M
authors.lastname: Aiach
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000990:Antithrombin III / Q000378:metabolism; D002918:Chymotrypsin / Q000037:antagonists & inhibitors / Q000097:blood*; D010450:Endopeptidases / Q000097:blood; D005260:Female; D015844:Heparin Cofactor II / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010179:Pancreas / Q000378:metabolism; D010195:Pancreatitis / Q000378:metabolism*; D011480:Protease Inhibitors / Q000097:blood
chemical_list: D011480:Protease Inhibitors; D015844:Heparin Cofactor II; D000990:Antithrombin III; D010450:Endopeptidases; D002918:Chymotrypsin